Getinge Valuation
Is GETIBS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GETIBS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GETIBS (SEK200.05) is trading below our estimate of fair value (SEK386.95)
Significantly Below Fair Value: GETIBS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GETIBS?
Other financial metrics that can be useful for relative valuation.
| What is GETIBS's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | SEK 54.24b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.9x |
| Enterprise Value/EBITDA | 14.1x |
| PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does GETIBS's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 33.9x | ||
SN. Smith & Nephew | 42x | 22.7% | UK£9.8b |
NIOX NIOX Group | 25.5x | 17.1% | UK£280.8m |
CTEC ConvaTec Group | 40.5x | 21.0% | UK£4.8b |
EKF EKF Diagnostics Holdings | 27.7x | n/a | UK£132.2m |
GETIBS Getinge | 32.1x | 20.7% | SEK 54.2b |
Price-To-Earnings vs Peers: GETIBS is good value based on its Price-To-Earnings Ratio (32.1x) compared to the peer average (33.9x).
Price to Earnings Ratio vs Industry
How does GETIBS's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: GETIBS is expensive based on its Price-To-Earnings Ratio (32.1x) compared to the European Medical Equipment industry average (30.6x).
Price to Earnings Ratio vs Fair Ratio
What is GETIBS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 32.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GETIBS's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | SEK 200.05 | SEK 233.00 +16.5% | 14.0% | SEK 300.00 | SEK 190.00 | n/a | 8 |
| Oct ’25 | SEK 218.05 | SEK 233.00 +6.9% | 14.0% | SEK 300.00 | SEK 190.00 | n/a | 8 |
| Sep ’25 | n/a | SEK 230.00 0% | 14.2% | SEK 300.00 | SEK 190.00 | n/a | 8 |
| Aug ’25 | SEK 208.30 | SEK 230.00 +10.4% | 14.2% | SEK 300.00 | SEK 190.00 | n/a | 8 |
| Jul ’25 | n/a | SEK 225.44 0% | 15.8% | SEK 290.00 | SEK 165.00 | n/a | 9 |
| Jun ’25 | n/a | SEK 229.22 0% | 13.2% | SEK 300.00 | SEK 186.00 | n/a | 9 |
| May ’25 | SEK 229.50 | SEK 235.50 +2.6% | 12.2% | SEK 300.00 | SEK 186.00 | n/a | 10 |
| Apr ’25 | n/a | SEK 226.10 0% | 14.9% | SEK 300.00 | SEK 164.00 | n/a | 10 |
| Mar ’25 | n/a | SEK 227.10 0% | 15.2% | SEK 300.00 | SEK 164.00 | n/a | 10 |
| Feb ’25 | n/a | SEK 236.60 0% | 11.3% | SEK 300.00 | SEK 210.00 | n/a | 10 |
| Jan ’25 | n/a | SEK 228.56 0% | 12.8% | SEK 300.00 | SEK 190.00 | n/a | 9 |
| Dec ’24 | n/a | SEK 220.33 0% | 17.4% | SEK 300.00 | SEK 150.00 | n/a | 9 |
| Nov ’24 | n/a | SEK 210.89 0% | 14.7% | SEK 250.00 | SEK 150.00 | n/a | 9 |
| Oct ’24 | n/a | SEK 203.11 0% | 16.1% | SEK 250.00 | SEK 134.00 | SEK 218.05 | 9 |
| Sep ’24 | SEK 186.55 | SEK 203.11 +8.9% | 16.1% | SEK 250.00 | SEK 134.00 | n/a | 9 |
| Aug ’24 | SEK 193.40 | SEK 203.11 +5.0% | 16.1% | SEK 250.00 | SEK 134.00 | SEK 208.30 | 9 |
| Jul ’24 | SEK 186.10 | SEK 230.40 +23.8% | 19.9% | SEK 300.00 | SEK 139.00 | n/a | 10 |
| Jun ’24 | SEK 246.70 | SEK 265.30 +7.5% | 11.8% | SEK 300.00 | SEK 193.00 | n/a | 10 |
| May ’24 | SEK 271.60 | SEK 260.33 -4.1% | 11.6% | SEK 295.00 | SEK 193.00 | SEK 229.50 | 9 |
| Apr ’24 | SEK 249.60 | SEK 252.89 +1.3% | 8.6% | SEK 285.00 | SEK 208.00 | n/a | 9 |
| Mar ’24 | SEK 223.70 | SEK 253.44 +13.3% | 8.1% | SEK 285.00 | SEK 208.00 | n/a | 9 |
| Feb ’24 | SEK 240.30 | SEK 252.89 +5.2% | 7.9% | SEK 285.00 | SEK 208.00 | n/a | 9 |
| Jan ’24 | SEK 213.70 | SEK 264.33 +23.7% | 5.5% | SEK 285.00 | SEK 240.00 | n/a | 9 |
| Dec ’23 | SEK 232.00 | SEK 274.89 +18.5% | 5.4% | SEK 300.00 | SEK 250.00 | n/a | 9 |
| Nov ’23 | SEK 224.00 | SEK 273.63 +22.2% | 5.5% | SEK 300.00 | SEK 250.00 | n/a | 8 |
| Oct ’23 | SEK 185.25 | SEK 292.50 +57.9% | 8.6% | SEK 331.00 | SEK 250.00 | n/a | 6 |
Analyst Forecast: Target price is less than 20% higher than the current share price.